Hydralazine vs Minoxidil — Cost, Coverage & Plan Comparison

Pick the drugs you want to compare.

Up to 4 drugsCross-class or same-class

Start with the molecules your plan spends the most on. Most useful comparisons live within the same therapeutic class — switching across classes requires deeper clinical review.

Drug 1

Drug 2

Drug 3 (optional)

Drug 4 (optional)

Side by side, line by line.

Federal data onlyNo PBM pricing assumed

Compare across

11 dimensions

Arteriolar Vasodilator

Hydralazine

Brand: Hydralazine

First FDA approval: 1990-09-30

Arteriolar Vasodilator

Minoxidil

First FDA approval: 1988-11-14

Lowest NADACAcquisition cost floor across all NDCs

$0.027Per unit

$0.095Per unit

Average NADACAcross all dosage forms and strengths

$0.043Up to $0.077

$0.136Up to $0.171

Generic manufacturersActive ANDA holders — FDA Orange Book

1742 total ANDAs filed

36 total ANDAs filed

Annualized Part D spendCY2024 — CMS Part D Spending Dashboard

$119.9MFull year

$14.7MFull year

Part D claims (CY24)Total fills, all strengths

9.1M2.7M beneficiaries

996K361K beneficiaries

Avg cost per claimCalculated: total spend ÷ total claims

$13Per claim, all NDCs

$15Per claim, all NDCs

Part D plans surveyed2026 plan year — CMS Formulary file

329Across CMS plan year

Prior-authorization frictionPlan-NDC pairs requiring PA

0Zero PA friction

2Minimal friction

Step therapy appliedPlan-NDC pairs requiring step therapy

0None

FDA shortage statusLive cross-reference vs FDA Drug Shortage Database

Active shortageSee drug profile

NoneClear

Generic availableFDA Orange Book

Yes17 manufacturers

Yes3 manufacturers